株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

米国の乾癬向け生物製剤・バイオシミラー治療薬市場

The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis

発行 MP Advisors 商品コード 565345
出版日 ページ情報 英文 104 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.11円で換算しております。
Back to Top
米国の乾癬向け生物製剤・バイオシミラー治療薬市場 The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis
出版日: 2017年10月13日 ページ情報: 英文 104 Pages
概要

当レポートでは、米国における乾癬治療用の生物製剤・バイオシミラー市場について取り上げ、生物製剤治療薬の主な上市製品、パイプライン製品、成長に影響を及ぼす要因、および競合情勢、バイオシミラーの認可済み製品、治験中の製品、成長に影響を及ぼす要因、および競合情勢などについて、分析しています。

第1章 乾癬市場の概要

第2章 乾癬の生物製剤治療薬市場

  • イントロダクション・市場概要
  • 米国における生物製剤の収益分析
  • 乾癬治療薬の主な上市製品
    • Remicade (infliximab; Janssen)
    • Humira (adalimumab; AbbVie)
    • Stelara (ustekinumab; Janssen)
    • Cosentyx (secukinumab; Novartis)
    • Taltz (ixekizumab; Lilly)
    • Siliq (brodalumab; Valeant)
    • Tremfya (guselkumab; Janssen)
  • 乾癬治療薬の主なパイプライン製品
    • Tildrakizumab; Merck / Sun Pharma
    • Cimzia (certolizumab pegol; UCB/Dermira Pharmaceuticals)
    • Risankizumab; AbbVie/Boehringer Ingelheim
  • 生物製剤の成長促進因子・抑制因子
  • 競合情勢:認可製品
  • 競合情勢:パイプライン製品

第3章 乾癬のバイオシミラー市場

  • イントロダクション・市場概要
  • 認可済みバイオシミラー
    • 米国における認可済みバイオシミラー
    • 米国におけるバイオシミラーの収益分析
    • EUにおける認可済みバイオシミラー
  • パイプライン分析
    • 治験:Humira (adalimumab) のバイオシミラー
    • 治験:Enbrel (etanercept) のバイオシミラー
    • 治験:Remicade (infliximab) のバイオシミラー
  • バイオシミラー契約・提携
  • バイオシミラーの成長促進因子・抑制因子
  • 競合情勢:米国・EUにおける認可済みバイオシミラー
  • 競合情勢:TNFアルファ阻害バイオシミラーのパイプライン

参考資料

目次
Product Code: 4496

The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation biologics.

The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents. The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents.

Driven by improved efficacy, the first group of anti TNF treatments led by Enbrel, Humira and Remicade made strong penetration into the psoriasis market. However the emergence of the IL-17 inhibitor class driven by Novartis' Cosentyx and Eli Lilly's Talz have set a new benchmark for efficacy in moderate to severe psoriasis treatment with potential for safety improvement in comparison to the anti TNF drugs given their greater specificity in immune Suppression. MP Advisors expect the TNF class of drugs to lose share to the newer brands with improved clinical profiles in Psoriasis.

The market growth in psoriasis is driven by an upsurge in demand from new therapies in moderate to severe patient population which overshadows reduced pricing of branded TNF-α inhibitor and recent biosimilar launches. The psoriasis treatment market is facing increasing competitive pressure from a wave of biosimilar launches such as biosimilars of Janssen's Remicade, and Amgen's Enbrel with the impact of the headwinds expected to be more pronounced in the next few years.

Stelara has been an important growth driver of Janssen's immunology franchise in recent years, with overall global sales doubling from $1.5bn in 2013 to more than $3.2bn in 2016. However Stelara has started to face steeper competition from the IL-17 drug class. A new head-to-head study report IL-17 products to demonstrate superior efficacy to Stelara for psoriasis.

Table of Contents

Executive Summary

List of Figures

List of Tables

1. Psoriasis Market Overview

  • 1.1. Disease background
  • 1.2. Types of psoriasis
    • 1.2.1. Plaque psoriasis
    • 1.2.2. Guttate psoriasis
    • 1.2.3. Inverse (flexural) psoriasis
    • 1.2.4. Pustular psoriasis
    • 1.2.5. Erythrodermic psoriasis
  • 1.3. Pathophysiology
  • 1.4. Etiology
    • 1.4.1. Environmental factors
    • 1.4.2. Genetic factors
    • 1.4.3. Immunologic factors
  • 1.5. Risk factors and co-morbidities
  • 1.6. Epidemiology
  • 1.7. Treatment options
    • 1.7.1. Phototherapy
    • 1.7.2. Topical treatments
    • 1.7.3. Conventional systemic agents
    • 1.7.4. Other systemic drugs
    • 1.7.5. Biologics
  • 1.8. Treatment Guidelines
    • 1.8.1. Mild to moderate Psoriasis
    • 1.8.2. Moderate Psoriasis
    • 1.8.3. Moderate -to-severe psoriasis
    • 1.8.4. Severe psoriasis

2. Psoriasis Treatment Market for Biologics

  • 2.1. Introduction and Market Overview
  • 2.2. Revenue Analysis for Biologics in the U.S.
  • 2.3. Key marketed products for psoriasis treatment
    • 2.3.1. Remicade (infliximab; Janssen)
    • 2.3.2. Humira (adalimumab; AbbVie)
    • 2.3.3. Stelara (ustekinumab; Janssen)
    • 2.3.4. Cosentyx (secukinumab; Novartis)
    • 2.3.5. Taltz (ixekizumab; Lilly)
    • 2.3.6. Siliq (brodalumab; Valeant)
    • 2.3.7. Tremfya (guselkumab; Janssen)
  • 2.4. Key pipeline products for psoriasis treatment
    • 2.4.1. Tildrakizumab; Merck / Sun Pharma
    • 2.4.2. Cimzia (certolizumab pegol; UCB/Dermira Pharmaceuticals)
    • 2.4.3. Risankizumab; AbbVie/Boehringer Ingelheim
  • 2.5. Growth Drivers and Resistors for Biologics
    • 2.5.1. Growth Drivers:
    • 2.5.2. Resistors
  • 2.6. Competitive Landscape - Approved Products
  • 2.7. Competitive Landscape - Pipeline Products

3. Psoriasis Market for Biosimilars

  • 3.1. Introduction and Market Overview
  • 3.2. Approved biosimilars
    • 3.2.1. Approved biosimilars in the U.S.
    • 3.2.2. Revenue Analysis for Biosimilars in U.S.
    • 3.2.3. Approved biosimilars in the EU
  • 3.3. Pipeline Analysis
    • 3.3.1. Clinical development - Humira (adalimumab) biosimilars
    • 3.3.2. Clinical development - Enbrel (etanercept) biosimilars
    • 3.3.3. Clinical development - Remicade (infliximab) biosimilars
  • 3.4. Biosimilars deals and partnerships
  • 3.5. Growth Drivers and Resistors for Biosimilars
    • 3.5.1. Growth Drivers
    • 3.5.2. Resistors
  • 3.6. Competitive Landscape - Approved Biosimilars in the U.S. and EU
  • 3.7. Competitive Landscape - TNF α Inhibitors Biosimilars Pipeline

References:

Back to Top